Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era

Lignende værker

• A Phase 2 Study of a Non-myeloablative Allogeneic Stem Cell Transplant with Peri-transplant Rituximab in Patients with B-cell Lymphoid Malignancies: Favorably Durable Event-free Survival in Chemosensitive Patients
  af: Sauter, Craig S., et al.
  Udgivet: (2013)
• Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma
  af: Lin, Richard J., et al.
  Udgivet: (2020)
• The Potential Benefit of Allogeneic over Autologous Transplantation in Patients with Very Early Relapsed and Refractory Follicular Lymphoma with Prior Remission Duration of ≤ 12 Months
  af: Lunning, Matthew A., et al.
  Udgivet: (2016)
• Allogeneic Haematopoietic Cell Transplantation Impacts on Outcomes of Mantle Cell Lymphoma with TP53 Alterations
  af: Lin, Richard J., et al.
  Udgivet: (2018)
• Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect
  af: Maffini, Enrico, et al.
  Udgivet: (2018)